

PHARMACY BULLETIN

Hospital Canselor Tuanku Muhriz

RESULTS FROM DRUGS AND THERAPEUTICS COMMITTEE MEETING (JKTU 2/2021)

JKTU Meeting was held on 18th August 2021 to renew and discuss drug policies. The results was implemented on **1st October 2021**.

There are two interim decisions implemented and no new drug submission approved by the committee.

WHAT'S NEW?

Pantoprazole 40mg Inj. is in!

Geriatric Clinic may initiate 4 more drugs



Inj. Pantoprazole 40mg

Approved!

Proposal:

1. Restrict the use of **Esomeprazole 40mg Inj.** to patients with Upper GI Bleed (UGIB) only.
2. Use **Pantoprazole 40mg Inj.** for Gastric Outlet Obstruction (OOS), gastric & esophagus surgery (either cancer or bariatric) and 2nd line stress ulcer prophylaxis.
3. Use **Ranitidine 50mg Inj.** for 1st line stress ulcer prophylaxis.




Geriatric Clinic may initiate:

1. Quetiapine Tab.
2. Escitalopram Tab.
3. Sertraline Tab.
4. Mirtazapine Tab.

Approved!

Pharmacy Department will supply the listed drugs **indented only by Dr. Hazlina** under Geriatric Clinic.

**Drug Expenditure 1H2021:
Who has the largest piece of cake?**



COVID-19 BOOSTER SHOTS

Booster dose is an additional dose of vaccine given after the protection by the original shot(s) naturally starts to wane. It is designed to help people maintain their level immunity for longer period of time.

Based on RECoVam and NMRR ID studies, it is shown that **protection against COVID-19 wanes 3-5 months after vaccination.**

The Malaysia Drug Control Authority (DCA) has approved Comirnaty (Pfizer), CoronaVac (Sinovac/Pharmaniga Lifescience) and the AstraZeneca vaccines to be used as the booster dose for all citizens ages 18 years old and above.

Priority will be given following age sequence (age step down approach); frontliners; individuals with comorbidities; pregnant ladies; and individuals with the need to go abroad.

The CDC now recommends any of the available COVID-19 vaccines may be administered as a heterologous (mix-and-match) booster dose following completion of primary vaccination with a different available COVID-19 vaccine. **Heterologous dosing may be considered for the booster dose only.**

Recommended booster shot administered and type of vaccines schedule

	Type of vaccines (primary series)	When to received booster	Recommended type of booster doses
1	Comirnaty (Pfizer)	6 months after dose 2	Comirnaty (Pfizer) (PPP) or AstraZeneca (*PPA)
2	AstraZeneca	6 months after dose 2	AstraZeneca (AAA) or Comirnaty (Pfizer) (AAP)
3	CoronaVac (Sinovac)	3 months after dose 2	Comirnaty (Pfizer) (SSP) or AstraZeneca (*SSA) or CoronaVac (Sinovac) (SSS)
4	Covilo (Sinopharm)	3 months after dose 2	Comirnaty (Pfizer) (OOP) or AstraZeneca (*OOA)
5	Spikevax (Moderna)	6 months after dose 2	Comirnaty (Pfizer) (MMP) or AstraZeneca (*MMA)
6	Convidecia (CanSino)	6 months after dose 1	Comirnaty (Pfizer) (CP) or AstraZeneca (*CA)
7	Janssen (Johnson & Johnson)	2 months after dose 1	Comirnaty (Pfizer) (JP) or AstraZeneca (*JA)

***for people 50 years old and above**

Sources:

1. RECoVam (The Real World Evaluation of COVID-19 Vaccines under the Malaysia National COVID-19 Immunisation Program; NMRR ID: 21-1660-60697)
2. Technical Working Committee (TWG), COVID-19 Immunisation Task Force-Booster (CITF-B)

If you are eligible for the booster dose and have not received your appointment

Visit protecthealth.com.my and find you nearest Pusat Pemberian Vaksin (PPV)

Then contact the PPV of interest via walk-in, telephone, or email to register as the back-up list

PPUKM Formulary App is now available on:



A publication of Drug Information Centre

Editors

Izyan Diyana Ibrahim izyandi@ppukm.ukm.edu.my

Nur Hafiza Saripin nurhafiza@ppukm.ukm.edu.my

03-9145 5401/5415